Previous 10 | Next 10 |
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Jami Nachtsheim to its Board of Directors. Ms. Nachtsheim currently serves on the Board at Intuitive Surgical, the global market leader in robotic-assisted minimally invasive surgical systems. Ms. Nachtsheim brings nearly fo...
Cerus Corporation (CERS) Q4 2018 Earnings Conference Call February 26, 2019 16:30 ET Company Participants Tim Lee - Investor Relations Director Obi Greenman - President and Chief Executive Officer Kevin Green - Chief Financial Officer Vivek Jayaraman - Chief Commercial Officer ...
Cerus Corporation (Nasdaq: CERS) today announced complete financial results for the fourth quarter and year ended December 31, 2018. Recent developments and highlights include: Record fourth quarter product revenue of $16.5 million. Provided 2019 annual product revenue gui...
AAXN , ACAD , AKCA , ARNA , AXGN , BGS , BNFT , CERS , CLGX , CPE , CSGP , CW , DRQ , DVAX , ELF , ENPH , EOG , EVH , FOXF , FRPT , FTR , GWPH , HEI , HPR , HURN , HY , ICFI , IMAX , IMMR , INGN , INN , INSP , JAZZ , JBGS , MASI , MED , MELI , MGRC , M...
Cerus Corporation (Nasdaq:CERS) announced today that the Company will participate in two upcoming investor conferences. Obi Greenman, Cerus’ president and chief executive officer is scheduled to attend BTIG’s Annual Healthcare Conference in Snowbird Utah on Wednesday, Feb...
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Varonis Systems, Inc. (NASDAQ:VRNS), Dolby Laboratories (NYSE:DLB), Alder...
Cerus Corporation (Nasdaq:CERS) announced today that its fourth quarter and full-year 2018 results will be released on Tuesday, February 26, 2019, after the close of the stock market. The company will host a conference call and webcast at 4:30 P.M. EDT that afternoon, during which management...
Cerus Corporation (CERS) quietly negotiated through 2018, even though the company consistently upgraded their revenue guidance over the course of the year. Recently, the company announced their preliminary Q4 revenues, and Cerus totaled $16.5M compared to $16.2M during the same period 2017. ...
Cerus (NASDAQ: CERS ) announced preliminary Q4 product revenue of $16.5M and FY18 product revenue of $60.9M, exceeding its prior guidance of $58-60M. More news on: Cerus Corporation, Healthcare stocks news, Read more ...
2019 product revenue guidance of $70 million to $73 million, representing growth of 15% to 20% over preliminary 2018 results Cerus Corporation (Nasdaq:CERS) today announced unaudited preliminary product revenue for the fourth quarter and full year 2018 and provided 2019 product revenu...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...